Liting Zhai

Research assistant professor

The Chinese University of Hong Kong (CUHK)
Country flagHong Kong

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (6)

Year:

2026

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Although blocking the binding of vascular endothelial growth factor (VEGF) to neuropilin-2 (NRP2) on tumor cells is a potential strategy to treat aggressive carcinomas, a lack of effective reagents that can be used clinically has hampered this potential therapy. Here, we describe the generation of a fully humanized, high-affinity monoclonal antibody (aNRP2-10) that specifically inhibits the binding of VEGF to NRP2, conferring antitumor activity without causing toxicity. Using triple-negative breast cancer as a model, we demonstrated that aNRP2-10 could be used to isolate cancer stem cells (CSCs) from heterogeneous tumor populations and inhibit CSC function and epithelial-to-mesenchymal transition. aNRP2-10 sensitized cell lines, organoids, and xenografts to chemotherapy and inhibited metastasis by promoting the differentiation of CSCs to a state that is more responsive to chemotherapy and less prone to metastasis. These data provide justification for the initiation of clinical trials designed to improve the response of patients with aggressive tumors to chemotherapy using this monoclonal antibody.

Year:

2023

Collaborators (6)

Thibault Viennet

Assistant Professor

Aarhus University

DENMARK
View details

Ayush Kumar

University of Massachusetts Chan Medical School

UNITED STATES
View details

Arthur M. Mercurio

Professor and Vice Chair

University of Massachusetts Chan Medical School

UNITED STATES
View details

Laura Dassama

Assistant Professor

Stanford University

UNITED STATES
View details

Yu Tang

University of California, Berkeley

UNITED STATES
View details

Paula Welander

Stanford University

UNITED STATES
View details